Dear Women's Imaging Insider,
Nuclear breast imaging refers to everything from PET and positron emission mammography (PEM) to breast-specific gamma imaging (BSGI) and molecular breast imaging (MBI). The technology shows physiological changes that are usually indicators of cancer and that are detectable earlier than those identified by other imaging modalities.
So is nuclear breast imaging poised to become a mainstream breast cancer screening and diagnosis tool?
The answer is a qualified yes, according to a presentation given at the recent National Consortium of Breast Centers (NCBC) annual meeting in Las Vegas. Click here to read what Dr. Michael Linver of X-Ray Associates of New Mexico had to say about the future of nuclear breast imaging, particularly PEM.
Once you've read our Insider Exclusive, take a look at what else is going on in the Women's Imaging Digital Community:
- Read why Emory University researchers believe that the potential for lower radiation dose could turn DBT into a breast screening tool.
- Discover why FDG-PET/CT is useful for predicting the survival of breast cancer patients with hepatic metastases.
- Find out whether breast density notification laws are cause for celebration.
- Read why it's so important for breast centers to track their quality.
- Learn how politics may be blocking widespread use of breast MRI for implants.
As always, if you have a comment, report, or article idea to share about any aspect of women's imaging, I invite you to contact me.











![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)





